olanzapine
Nervous system (N05)US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor antagonist
pharma · Schizophrenia
Guangzhou Psychiatric Hospital
Guangzhou Psychiatric Hospital drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Guangzhou Psychiatric Hospital pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Guangzhou Psychiatric Hospital drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.